JP2008513370A - 障害を処置する方法 - Google Patents

障害を処置する方法 Download PDF

Info

Publication number
JP2008513370A
JP2008513370A JP2007531465A JP2007531465A JP2008513370A JP 2008513370 A JP2008513370 A JP 2008513370A JP 2007531465 A JP2007531465 A JP 2007531465A JP 2007531465 A JP2007531465 A JP 2007531465A JP 2008513370 A JP2008513370 A JP 2008513370A
Authority
JP
Japan
Prior art keywords
compound
alkyl
disorder
sirt1
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513370A5 (https=
Inventor
アンドリュー ナッパー，
ピーター ディステファーノ，
ローリー カーティス，
ジェフリー ヒクソン，
トーマス マクドナー，
エル． ジュリー フーバー，
ジョナサン エム． ソロモン，
ラッセル ジェイ． トーマス，
ジャン−フランソア ポン，
Original Assignee
エリクシアー ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/940,269 external-priority patent/US20050209300A1/en
Application filed by エリクシアー ファーマシューティカルズ， インコーポレイテッド filed Critical エリクシアー ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008513370A publication Critical patent/JP2008513370A/ja
Publication of JP2008513370A5 publication Critical patent/JP2008513370A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2007531465A 2004-09-13 2005-09-13 障害を処置する方法 Pending JP2008513370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/940,269 US20050209300A1 (en) 2003-09-12 2004-09-13 Methods of treating a disorder
US11/077,664 US20060074124A1 (en) 2003-09-12 2005-03-11 Methods of treating a disorder
PCT/US2005/032760 WO2006031894A2 (en) 2004-09-13 2005-09-13 Methods of treating a disorder

Publications (2)

Publication Number Publication Date
JP2008513370A true JP2008513370A (ja) 2008-05-01
JP2008513370A5 JP2008513370A5 (https=) 2008-09-18

Family

ID=36060677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531465A Pending JP2008513370A (ja) 2004-09-13 2005-09-13 障害を処置する方法

Country Status (7)

Country Link
US (4) US20060074124A1 (https=)
EP (1) EP1793817A4 (https=)
JP (1) JP2008513370A (https=)
AU (1) AU2005284851A1 (https=)
CA (1) CA2578355A1 (https=)
MX (1) MX2007002816A (https=)
WO (1) WO2006031894A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087107A1 (ja) * 2009-01-29 2010-08-05 北海道公立大学法人札幌医科大学 メラノーマの転移抑制剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20090022694A1 (en) * 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
CN105481788A (zh) * 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008054767A2 (en) * 2006-10-30 2008-05-08 University Of Southern California N4 modifications of pyrimidine analogs and uses thereof
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
WO2008119070A1 (en) * 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
EA019713B1 (ru) * 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
WO2010077642A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
BRPI1014821A2 (pt) * 2009-04-09 2016-04-05 Boehringer Ingelheim Int "inibidores de replicação de hiv"
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
DK2911650T3 (da) * 2012-10-29 2019-11-18 Agency Science Tech & Res Hidtil ukendt reagens til gen-lægemiddel-terapeutika
EP3230279A1 (en) 2014-12-10 2017-10-18 Massachusetts Institute of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
CA3068005A1 (en) * 2017-06-19 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2020083933A1 (en) * 2018-10-23 2020-04-30 Mexav Biotech Ag Fusion polypeptides and therapeutic applications thereof
PY2438446A (es) * 2023-05-16 2025-06-18 Aop Orphan Ip Ag Preparación de (s)-6-cloro-2,3,4,9- tetrahidro-1h-carbazol-1-carboxamida en forma enantioméricamente enriquecida mediante proceso de resolución
CN120118019A (zh) * 2023-12-08 2025-06-10 苏州湃芮生物科技有限公司 一种RNA m6A调控剂的共晶形式及其制备方法与应用
CN120136769A (zh) * 2023-12-11 2025-06-13 苏州湃芮生物科技有限公司 一种RNA m6A调控剂的结晶形式及其制备方法与应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4876865A (https=) * 1971-12-30 1973-10-16
US3769298A (en) * 1971-04-02 1973-10-30 Pfizer Substituted aminomethylcarbazoles
JPS4941367A (https=) * 1972-05-25 1974-04-18
JPS5069072A (https=) * 1973-07-18 1975-06-09
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
WO2003051837A2 (de) * 2001-12-14 2003-06-26 Zentaris Gmbh Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
WO2003062392A2 (en) * 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2004055169A2 (en) * 2002-12-13 2004-07-01 Elixir Pharmaceuticals, Inc. Cytochrome c acetylation
WO2005026112A2 (en) * 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005072408A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Treating a viral disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057640A (en) * 1973-07-18 1977-11-08 Schering Aktiengesellschaft 5,6,7,8:Tetrahydrocarbazole-1-carboxylic acid derivatives
DE2431292A1 (de) 1974-06-27 1976-01-15 Schering Ag Neue carbazol-derivate
HUT76923A (hu) * 1994-07-27 1998-01-28 Sankyo Company Limited Muszkarinreceptorokra alloszterikus hatást kifejtő heterociklusos vegyületek
JP2000508302A (ja) * 1996-04-04 2000-07-04 エフ．ホフマン―ラ ロッシュ エイジー 抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用
US20010039012A1 (en) * 1999-06-14 2001-11-08 Lapidus Stanley N. Methods for diagnostic screening
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769298A (en) * 1971-04-02 1973-10-30 Pfizer Substituted aminomethylcarbazoles
JPS4876865A (https=) * 1971-12-30 1973-10-16
JPS4941367A (https=) * 1972-05-25 1974-04-18
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
JPS5069072A (https=) * 1973-07-18 1975-06-09
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
WO2003051837A2 (de) * 2001-12-14 2003-06-26 Zentaris Gmbh Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
WO2003062392A2 (en) * 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2004055169A2 (en) * 2002-12-13 2004-07-01 Elixir Pharmaceuticals, Inc. Cytochrome c acetylation
WO2005026112A2 (en) * 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005072408A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Treating a viral disorder

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087107A1 (ja) * 2009-01-29 2010-08-05 北海道公立大学法人札幌医科大学 メラノーマの転移抑制剤

Also Published As

Publication number Publication date
US20060074124A1 (en) 2006-04-06
US20090306168A1 (en) 2009-12-10
WO2006031894A2 (en) 2006-03-23
US20140163029A1 (en) 2014-06-12
US8486990B2 (en) 2013-07-16
EP1793817A2 (en) 2007-06-13
MX2007002816A (es) 2007-05-16
EP1793817A4 (en) 2008-04-02
WO2006031894A3 (en) 2006-12-21
CA2578355A1 (en) 2006-03-23
AU2005284851A1 (en) 2006-03-23
US20160113903A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US8486990B2 (en) SirT inhibitors that bind to NAD
JP4908215B2 (ja) 疾患の治療法
US20050250794A1 (en) Methods of treating a disorder
JP2022116307A (ja) 障害を治療するための５ｈｔ作動薬
US8153803B2 (en) Compositions and methods for modulating sirtuin activity
US20180050989A1 (en) Aldehyde trapping compounds and uses thereof
US20090069559A1 (en) Compositions and methods for modulating sirtuin activity
US20080214800A1 (en) Sirt inhibitors that bind to nad
CA2443031A1 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
CN101035527A (zh) 治疗疾病的方法
WO2006050451A2 (en) Methods and compositions to treat motor neuron disease
JPWO2019031425A1 (ja) 運動ニューロン疾患治療剤
US20150065486A1 (en) Methods for treating polycystic kidney disease
KR20030085421A (ko) ｐ53 또는 ｐ21 유전자 변이에 의해 ｐ53 또는 ｐ21유전자 기능을 상실한 암의 치료를 위한 액틴 저해제를포함하는 약학 조성물
CN113135907B (zh) 一种提高α-微管蛋白乙酰化水平的化合物及其制备方法与应用
US7265248B1 (en) Compositions and methods for the treatment of malaria
CN119923380A (zh) N-取代苯烷基胺及其作为治疗剂的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120322